The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial

Creative Commons License

Linjawi S., Sothiratnam R., SARI R., Andersen H., Hiort L. C., Rao P.

PRIMARY CARE DIABETES, cilt.9, sa.5, ss.370-376, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 9 Sayı: 5
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1016/j.pcd.2014.11.001
  • Dergi Adı: PRIMARY CARE DIABETES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.370-376
  • Anahtar Kelimeler: Biphasic insulin, Sitagliptin, Type 2 diabetes, Randomized trial, COMBINATION, EFFICACY, SAFETY, GLARGINE, MELLITUS
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Aims: Investigate efficacy and tolerability of intensifying diabetes treatment with onceor twice-daily biphasic insulin aspart 30 (BIAsp 30) added to sitagliptin, and twice-daily BIAsp 30 without sitagliptin in patients with type 2 diabetes (T2D) inadequately controlled on sitagliptin.